How is the effectiveness of tucatinib evaluated?

Tucatinib is a targeted drug targeting the activity of HER2 (ERBB2) and is mainly used to treat HER2-positive metastatic breast cancer.

In theHER2CLIMBpivotal clinical trial, tucatinib plus trastuzumab and capecitabine was compared with placebo plus trastuzumab and capecitabine. The results showed that the tucatinib combination group significantly prolonged the progression-free survival (PFS) and overall survival (OS) of the patients. Specifically, the median PFS was 7.8 months in the tucatinib group and 5.6 months in the placebo group; The 2-year OS rate was 44.9% in the placebo group, compared with 26.6% in the placebo group.

Tucatinib has also shown significant efficacy in patients with brain metastases. HER2CLIMBThe trial showed that patients with brain metastases in the tucatinib combination group 1 years The PFS rate was 24.9% compared with 0% in the placebo group.

Tucatinib is often combined with other drugs to increase its effectiveness. For example, the combination with trastuzumab and capecitabine has been shown to significantly improve survival in patients with HER2-positive breast cancer.

In addition, studies have shown that tucatinib combined with letrozole, palbociclib and other drugs has also achieved significant results in the treatment ofHR+/HER2+ breast cancer.

Tucatinib demonstrated good safety and tolerability in clinical trials. Although some patients may experience some adverse reactions, such as diarrhea, nausea, fatigue, etc., these reactions are usually controllable and reversible.

The favorable safety and tolerability profile enable tucatinib as a long-term treatment option, thereby improving patient survival and quality of life.

In actual clinical applications, tucatinib has also received positive feedback from patients and doctors. Many patients said that after using tucatinib, their condition was effectively controlled and their quality of life was improved.

Doctors have also recognized the efficacy of tucatinib and believe that it is an effective and safe HER2 positive breast cancer treatment drug.

References:

https://www.nejm.org/doi/full/10.1056/NEJMoa1914609